Mount Vernon Cancer Centre

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Prostate cancer1 trial

Phase

• Phase 33 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Royal Marsden NHS Foundation Trust2 trials
• Jazz Pharmaceuticals1 trial
• Ourotech, Inc.1 trial
• Scancell Ltd1 trial
• Velindre NHS Trust1 trial

Running trials

• Not yet recruiting

  iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

  NCT07815574· Phase 3· Scancell Ltd· Source

  Contact: Heather Shaw (principal investigator)

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

  Contact: Clinical Trial Disclosure & Transparency

• Active, not recruiting

  Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

  NCT04920708· Phase 2· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

  NCT01992952· Phase 1/2· Velindre NHS Trust· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting

Closed trials

• Terminated

  Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2

  NCT06264479· Ourotech, Inc.· Source